Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-201 in Moderate to Severe Persistent Asthma
NCT04773678Phase 2Completed
- Sponsor
- Connect Biopharma
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of rademikibart in asthma (3 arms), sponsored by Connect Biopharma. Primary endpoint: Absolute change in prebronchodilator (trough) forced expiratory volume in the first second of expiration at Week 12. Started May 2021; status: completed.
02
Drugs
rademikibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04773678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773678.